Cargando…

A phase-1b study of everolimus plus paclitaxel in patients with small-cell lung cancer

BACKGROUND: The mammalian target of rapamycin (mTOR) pathway is dysregulated in small-cell lung cancer (SCLC) and everolimus is an oral mTOR inhibitor. METHODS: This phase-1b study assessed everolimus safety at the levels of 2.5, 5, or 10 mg once daily in combination with paclitaxel (175 mg m(−2)) o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sun, J M, Kim, J R, Do, I G, Lee, S Y, Lee, J, Choi, Y L, Ahn, J S, Ahn, M J, Park, K
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2013
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3776982/ https://www.ncbi.nlm.nih.gov/pubmed/23963141 http://dx.doi.org/10.1038/bjc.2013.467

Ejemplares similares

Three-week schedule of irinotecan plus cisplatin in patients with previously untreated extensive-stage small-cell lung cancer
por: Hong, Y S, et al.
Publicado: (2006)

Phase II study of everolimus with biomarker exploration in patients with advanced gastric cancer refractory to chemotherapy including fluoropyrimidine and platinum
por: Yoon, D H, et al.
Publicado: (2012)

Phase I study of temozolomide plus paclitaxel in patients with advanced malignant melanoma and associated in vitro investigations
por: Azzabi, A, et al.
Publicado: (2005)

Phase II and pharmacological study of oral paclitaxel (Paxoral) plus ciclosporin in anthracycline-pretreated metastatic breast cancer
por: Helgason, H H, et al.
Publicado: (2006)

Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer
por: McKeage, M J, et al.
Publicado: (2008)

Phase I trial of capecitabine plus everolimus (RAD001) in patients with previously treated metastatic gastric cancer
por: Lim, Taekyu, et al.
Publicado: (2011)

Phase II study of pazopanib monotherapy in metastatic gastroenteropancreatic neuroendocrine tumours
por: Ahn, H K, et al.
Publicado: (2013)

UFT plus gemcitabine combination chemotherapy in patients with advanced non-small-cell lung cancer: a multi-institutional phase II trial
por: Ichinose, Y, et al.
Publicado: (2005)

A phase II study of biweekly dose-intensified oral capecitabine plus irinotecan (bXELIRI) for patients with advanced or metastatic gastric cancer
por: Oh, S C, et al.
Publicado: (2007)

Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancer
por: Paz-Ares, L, et al.
Publicado: (2008)

A randomised phase II study of weekly paclitaxel or vinorelbine in combination with cisplatin against inoperable non-small-cell lung cancer previously untreated
por: Chen, Y-M, et al.
Publicado: (2004)

Everolimus-Eluting versus Paclitaxel-Eluting Stents in Percutaneous Coronary Intervention: Meta-Analysis of Randomized Trials
por: Alazzoni, Ashraf, et al.
Publicado: (2012)

A phase II study of paclitaxel and capecitabine as a first-line combination chemotherapy for advanced gastric cancer
por: Kang, H J, et al.
Publicado: (2008)

Multicenter phase II study of docetaxel plus oxaliplatin combination chemotherapy in patients with advanced gastric cancer: Daegu Gyeongbuk Oncology Group
por: Kim, J G, et al.
Publicado: (2008)

Phase 1 study of lenvatinib combined with carboplatin and paclitaxel in patients with non-small-cell lung cancer
por: Nishio, M, et al.
Publicado: (2013)

Phase II study of pemetrexed in combination with cisplatin in patients with advanced urothelial cancer: the PECULIAR study (KCSG 10–17)
por: Choi, Y J, et al.
Publicado: (2015)

Front-line paclitaxel and irinotecan combination chemotherapy in advanced non-small-cell lung cancer: a phase I–II trial
por: Stathopoulos, G P, et al.
Publicado: (2005)

A single institutional experience of thymic epithelial tumours over 11 years: clinical features and outcome and implications for future management
por: Lee, H-S, et al.
Publicado: (2007)

Adjuvant chemotherapy for gastric cancer: a randomised phase 3 trial of mitomycin-C plus either short-term doxifluridine or long-term doxifluridine plus cisplatin after curative D2 gastrectomy (AMC0201)
por: Kang, Y-K, et al.
Publicado: (2013)

Economic evaluation for the UK of nab-paclitaxel plus gemcitabine in the treatment of metastatic pancreas cancer
por: Gharaibeh, M, et al.
Publicado: (2015)

Epirubicin/paclitaxel/etoposide in extensive-stage small-cell lung cancer: a phase I–II study
por: Tibaldi, C, et al.
Publicado: (2006)

A randomised, double-blind, placebo-controlled multi-centre phase III trial of XELIRI/FOLFIRI plus simvastatin for patients with metastatic colorectal cancer
por: Lim, S H, et al.
Publicado: (2015)

Phase I/II study of cisplatin combined with weekly paclitaxel in patients with advanced non-small-cell lung cancer
por: Yoshimura, N, et al.
Publicado: (2004)

Survival, quality-adjusted survival, and other clinical end points in older advanced non-small-cell lung cancer patients treated with albumin-bound paclitaxel
por: Langer, C J, et al.
Publicado: (2015)

Concurrent chemotherapy (carboplatin, paclitaxel, etoposide) and involved-field radiotherapy in limited stage small cell lung cancer: a Dutch multicenter phase II study
por: Baas, P, et al.
Publicado: (2006)

Phase 1B trial of Nab-paclitaxel plus gemcitabine, capecitabine, and cisplatin (PAXG regimen) in patients with unresectable or borderline resectable pancreatic adenocarcinoma
por: Reni, Michele, et al.
Publicado: (2016)

Phase I study of axitinib combined with paclitaxel, docetaxel or capecitabine in patients with advanced solid tumours
por: Martin, L P, et al.
Publicado: (2012)

Second-line paclitaxel in non-small cell lung cancer initially treated with cisplatin: a study by the European Lung Cancer Working Party
por: Berghmans, T, et al.
Publicado: (2007)

Prophylactic use of lamivudine for hepatitis B exacerbation in post-operative breast cancer patients receiving anthracycline-based adjuvant chemotherapy
por: Yun, J, et al.
Publicado: (2011)

Randomized Phase II Study of Weekly Paclitaxel plus Carboplatin Versus Biweekly Paclitaxel plus Carboplatin for Patients with Previously Untreated Advanced Non‐Small Cell Lung Cancer
por: Takayama, Koichi, et al.
Publicado: (2019)

A double-blind, randomized phase II study of dicycloplatin plus paclitaxel versus carboplatin plus paclitaxel as first-line therapy for patients with advanced non-small-cell lung cancers
por: Liu, Ke-Jun, et al.
Publicado: (2014)

Randomised phase II trial of irinotecan plus cisplatin vs irinotecan, cisplatin plus etoposide repeated every 3 weeks in patients with extensive-disease small-cell lung cancer
por: Sekine, I, et al.
Publicado: (2008)

A phase II study of gemcitabine and cisplatin plus sorafenib in patients with advanced biliary adenocarcinomas
por: Lee, J K, et al.
Publicado: (2013)

Beneficial Effects of the mTOR Inhibitor Everolimus in Patients with Advanced Medullary Thyroid Carcinoma: Subgroup Results of a Phase II Trial
por: Schneider, T. C., et al.
Publicado: (2015)

Weekly Paclitaxel plus Capecitabine versus Docetaxel Every 3 Weeks plus Capecitabine in Metastatic Breast Cancer
por: Wist, E. A., et al.
Publicado: (2012)

Phase II study of irinotecan combined with carboplatin in previously untreated small-cell lung cancer
por: Kinoshita, A, et al.
Publicado: (2006)

A phase I and pharmacokinetic study of NK105, a paclitaxel-incorporating micellar nanoparticle formulation
por: Hamaguchi, T, et al.
Publicado: (2007)

Phase I study of weekly paclitaxel in combination with pazopanib and lapatinib in advanced solid malignancies
por: Tan, A R, et al.
Publicado: (2014)

Phase I/II study of S-1 combined with paclitaxel in patients with unresectable and/or recurrent advanced gastric cancer
por: Mochiki, E, et al.
Publicado: (2006)

Phase II study of gemcitabine plus oxaliplatin as first-line chemotherapy for advanced non-small-cell lung cancer
por: Cappuzzo, F, et al.
Publicado: (2005)

Cannot write session to /tmp/vufind_sessions/sess_v2d6ck3mkiflqte3qksb755o92